Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759273 | 1.00 | MRGPRX4 (0.51) | MRGPRX4RAB9AALDH1A1HTTLMNA | |
| SCHEMBL4356098 | 0.86 | CES2 (0.43) | MRGPRX4RAB9ANPC1GAASMN1; SMN2 | |
| SCHEMBL1401550 | 0.84 | MRGPRX4 (0.55) | MRGPRX4RAB9AHTTLMNAMAPK1 | |
| SCHEMBL6181668 | 0.84 | PKM (0.52) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL4124943 | 0.84 | EPHX2 (0.55) | RAB9AALDH1A1HTTLMNAMAPK1 | |
| SCHEMBL4259943 | 0.82 | MRGPRX4 (0.50) | MRGPRX4RAB9AALDH1A1HTTLMNA | |
| SCHEMBL3688309 | 0.82 | PARP1 (0.46) | MAPK1MEN1KMT2ATSHRHTR7 | |
| SCHEMBL31279141 | 0.82 | PARP1 (0.46) | MAPK1MEN1KMT2ATSHRHTR7 | |
| SCHEMBL31435271 | 0.82 | CES2 (0.41) | MRGPRX4RAB9AALDH1A1NPC1GAA | |
| SCHEMBL27605506 | 0.82 | MAPT (0.51) | ALDH1A1HTTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090928-A9 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250346604-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS | 2025-11-13 | — | — | US | disclosed |
| US-20250235453-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS | 2025-07-24 | — | — | US | disclosed |
| WO-2025090928-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024091473-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023076259-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-2185537-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | MRGPRX4 80/4885RAB9A 3996/4885ALDH1A1 2865/4885 |
| US-20250346604-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | RAC1, TNK2, GDI2 | MRGPRX4 1331/4885RAB9A 63/4885ALDH1A1 2294/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MRGPRX4 17/4885RAB9A 2883/4885ALDH1A1 1599/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MRGPRX4 17/4885RAB9A 2883/4885ALDH1A1 1599/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | MRGPRX4 167/4885RAB9A 3419/4885ALDH1A1 1316/4885 |
| US-20250235453-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | RAC1, TNK2, GDI2 | MRGPRX4 1331/4885RAB9A 63/4885ALDH1A1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.